Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears poised for rapid growth as the application space for EEG-based solutions expands. “With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the company appears well-placed within the growing brain monitoring space,” reads a recent article. This comes as the brain-computer interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. It is a promising approach to overcoming paralysis by decoding brain signals directly from the scalp and translating them into movements of a virtual or robotic effector. This powerful technology can provide opportunities for motor rehabilitation from a number of conditions and even help patients who’ve lost the ability to speak. “Committed to pushing the boundaries of what’s possible in the neurology space, Brain Scientific brings the groundbreaking technology that aims to enable what was inconceivable until recently.”
To view the full article, visit https://ibn.fm/oiwdT
About Brain Scientific Inc.
Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
Cardio Diagnostics Holdings (NASDAQ: CDIO) is positioned for opportunity as cardiovascular diagnostics are undergoing a transformation as…
Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company, announced that the U.S. Food and Drug…
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biotechnology company, reported continued progress on its proprietary AI…
HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, will host a…
Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its efforts to…
This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid…